320 related articles for article (PubMed ID: 20923544)
1. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.
Li J; Zhao X; Chen L; Guo H; Lv F; Jia K; Yv K; Wang F; Li C; Qian J; Zheng C; Zuo Y
BMC Cancer; 2010 Oct; 10():529. PubMed ID: 20923544
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
3. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
[TBL] [Abstract][Full Text] [Related]
4. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
Izar B; Sharfman W; Hodi FS; Lawrence D; Flaherty KT; Amaravadi R; Kim KB; Puzanov I; Sosman J; Dummer R; Goldinger SM; Lam L; Kakar S; Tang Z; Krieter O; McDermott DF; Atkins MB
Cancer Med; 2017 Aug; 6(8):1904-1914. PubMed ID: 28719152
[TBL] [Abstract][Full Text] [Related]
5. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Clark JW; Eder JP; Ryan D; Lathia C; Lenz HJ
Clin Cancer Res; 2005 Aug; 11(15):5472-80. PubMed ID: 16061863
[TBL] [Abstract][Full Text] [Related]
7. Apatinib in recurrent anaplastic meningioma: a retrospective case series and systematic literature review.
Wang Y; Li W; Jing N; Meng X; Zhou S; Zhu Y; Xu J; Tao R
Cancer Biol Ther; 2020 Jul; 21(7):583-589. PubMed ID: 32212907
[TBL] [Abstract][Full Text] [Related]
8. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
9. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.
Kang Z; Li S; Lin Y; Li Y; Mao Y; Zhang J; Lei T; Wang H; Su Y; Yang Y; Qiu J; Li W
Invest New Drugs; 2023 Apr; 41(2):296-305. PubMed ID: 36884148
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
12. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
[TBL] [Abstract][Full Text] [Related]
13. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Moore M; Hirte HW; Siu L; Oza A; Hotte SJ; Petrenciuc O; Cihon F; Lathia C; Schwartz B
Ann Oncol; 2005 Oct; 16(10):1688-94. PubMed ID: 16006586
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP; Shapiro GI; Appleman LJ; Zhu AX; Miles D; Keer H; Cancilla B; Chu F; Hitchcock-Bryan S; Sherman L; McCallum S; Heath EI; Boerner SA; LoRusso PM
Clin Cancer Res; 2010 Jul; 16(13):3507-16. PubMed ID: 20472683
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.
Doi T; Matsubara N; Kawai A; Naka N; Takahashi S; Uemura H; Yamamoto N
Invest New Drugs; 2020 Aug; 38(4):1175-1185. PubMed ID: 31820255
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hoekstra R; Dumez H; Eskens FA; van der Gaast A; Planting AS; de Heus G; Sizer KC; Ravera C; Vaidyanathan S; Bucana C; Fidler IJ; van Oosterom AT; Verweij J
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6908-15. PubMed ID: 16203782
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
[TBL] [Abstract][Full Text] [Related]
18. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
20. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
